Top Banner

of 14

Ihs Global Pharma

Jun 02, 2018

ReportDownload

Documents

leohytu

  • 8/10/2019 Ihs Global Pharma

    1/14

    Gustav Ando

    Director

    Healthcare and Pharma

    Key Industry Drivers for 2014

    IHS Healthcare and Pharma

  • 8/10/2019 Ihs Global Pharma

    2/14

    1. The foundations for economic

    recovery continue to be in place

    IHS Healthcare and Pharma Key Industry Drivers for 2014 I Copyright 2014 IHS

    1. The foundations for economic recovery

    continue to be in place The global economy is expected to see

    a recovery in 2014 and 2015. However,

    there is a marked shift in dynamics over

    where the growth is expected. Average

    growth in emerging markets has fallensteadily to 4.7% in 2013, while the

    outlook for advanced markets is stronger

    than it has been for many years.

    Add to this the scarring experience several pharmaceutical companies had in Chinaamid a

    clampdown on marketing practicesand we see several significant players deciding to reset

    their agenda in emerging markets.

    While much attention is focused on the detrimental impact of healthcare reform in general,

    the impact will be felt hardest in key European markets especially Germany, France, UK,

    Southern Europe and the Nordics. Interestingly, the global pharmaceutical industry continues

    to be heavy dependant and focused on these regions.

  • 8/10/2019 Ihs Global Pharma

    3/14

    1. The foundations for economic

    recovery continue to be in place

    IHS Healthcare and Pharma Key Industry Drivers for 2014 I Copyright 2014 IHS

    2. The United States first full year of ACA

    The focus has been on the stuttering implementation of Medicaid

    expansion amid continued political resistance. Midterm elections will

    be critical in deciding how fast or slow implementation will happen.

    The bulk of the patent cliff is over, meaning that the market will return to

    being driven significant increases in pharmaceutical prices

    Health spend will grew 5% in 2013 and is expecting to rise above 6% in

    2014 our assumptions are based on a more gradualistic impact of

    Medicaid expansion than for example CMS (which subsequently revisedits estimations).

    Pharmaceutical prices declined dramatically in September 2013 and

    there is more pushback from payers on pricing.

  • 8/10/2019 Ihs Global Pharma

    4/14

    1. The foundations for economicrecovery continue to be in place

    IHS Healthcare and Pharma Key Industry Drivers for 2014 I Copyright 2014 IHS

    3. Europe/Eurozone instability will continue to suppress

    public health expenditure

    Greece and Italy will experience negative and lower growth

    (respectively), with Italy implementing its spending review. Spain is also

    declining significantly due to co-payments and procurement.

    Health spend will grow significantly in France with newly implementedprice cuts, prescription controls, and a focus on home care. The

    transition to ITR is having a significant impact.

    Germany has abandoned the retroactive benefit assessments, but looks

    to prolong price freezes, and there may be other non-AMNOG-related

    reforms.

    UKs VBP pushed towards the end of the year

  • 8/10/2019 Ihs Global Pharma

    5/14

    1. The foundations for economicrecovery continue to be in place

    IHS Healthcare and Pharma Key Industry Drivers for 2014 I Copyright 2014 IHS

    4. Secondary emerging markets

    are expanding healthcare insurance

    The Philippines continues to be a fast-growing market, and a law

    introducing universal health was enacted by President Aquino in June

    2013.

    Indonesia's universal healthcare coverage was launched on 1 January2014 with a goal of 100% coverage in five years for the world's fourth

    most populous country. The universal healthcare system, Jaminan

    Kesehatan Nasional (JKN), will transform Indonesia from a primarily self-

    paid market to an insurance-driven healthcare market.

    Markets such as Nigeria, UAE and Qatar are also expanding their

    insurance coverage.

  • 8/10/2019 Ihs Global Pharma

    6/14

    1. The foundations for economicrecovery continue to be in place

    IHS Healthcare and Pharma Key Industry Drivers for 2014 I Copyright 2014 IHS

    5. Reimbursement continues to offer a mixed picture

  • 8/10/2019 Ihs Global Pharma

    7/14

    1. The foundations for economicrecovery continue to be in place

    IHS Healthcare and Pharma Key Industry Drivers for 2014 I Copyright 2014 IHS

    2014 will be a comparatively quiet year among patent expirations

    following the turbulent 2011-2013 period.

    The patents to expire include drugs such as Temodar, Evista, Avelox,

    Nasonex, and Nexium.

    In the biosimilars space, there are more potential negative drivers with

    challenges to Herceptin, Lantus and Rituxan in Europe.

    6. Patent expirations continue to be a significant driver,

    but it is a comparatively quiet year

  • 8/10/2019 Ihs Global Pharma

    8/14

    1. The foundations for economicrecovery continue to be in place

    IHS Healthcare and Pharma Key Industry Drivers for 2014 I Copyright 2014 IHS

    7. IRP baskets continue to evolve

    Portugal has already changed its basket and there could be changes in

    Turkey.

    Increasing fears that prices in New Zealand and South Korea could trickle

    into much more important markets.

    Price harmonisation efforts in GCC (collective procurement starting 2014)

    and Baltics.

    Colombia is launching its new reference pricing system which will target

    patented and generic drugs, whilst Mexico is looking at internationalreference pricing in 2014 during next round of negotiations.

  • 8/10/2019 Ihs Global Pharma

    9/14

    1. The foundations for economicrecovery continue to be in place

    IHS Healthcare and Pharma Key Industry Drivers for 2014 I Copyright 2014 IHS

    8. Drug shortages will continue, but clampdowns

    on parallel exports are seen in many countries

    Drug shortages will increase due to parallel exportwith several

    countries (Greece, Czech Republic, Slovakia and Romania, among others)

    banning exports of certain drugs.

    Italy and Bulgaria are also looking to curb parallel exports. Poland hashighlighted the issue as an area of growing concern.

    Whilst parallel trade continues to be a significant negative driver,

    governments are beginning to realize the negative consequences on a

    stable supply of essential pharmaceuticals

  • 8/10/2019 Ihs Global Pharma

    10/14

    1. The foundations for economicrecovery continue to be in place

    IHS Healthcare and Pharma Key Industry Drivers for 2014 I Copyright 2014 IHS

    9. Price cuts in Japan but some incentives forinnovation

    The government has concluded that the average price cut rate in April

    2014 will be 5.7%excluding the impact of a sales tax hike.

    However, Japan remains one of the few major markets where there are

    constructive discussions around increasing the reward for innovation.

    The country is continuing its pilot programme of exempting innovative

    products which fulfil certain criteria from the price cuts although it

    backed down from its December 2013 proposal to turn the pilot

    programme into a permanent fixture on the market.

  • 8/10/2019 Ihs Global Pharma

    11/14

    1. The foundations for economicrecovery continue to be in place

    IHS Healthcare and Pharma Key Industry Drivers for 2014 I Copyright 2014 IHS

    10. New technology developments

    At the tail-end of 2013, the FDA approved Gileads Sovaldi (sofosbuvir),

    the first approval of an all-oral, interferon-free combination therapy in

    hepatitis C. Whilst J&Js NS3/4A protease inhibitor Olysio was approved

    the month before, Sovaldis approval very much sets the tone for thenew drug catalysts in 2014, and it is the biggest new drug launch that the

    industry has seen for some time.

    2014 is generally felt to be a transformational year for immunotherapies

    and drugs targeting PD-1. Two therapies are in the final stages of

    development here: Bristol-Myers Squibbs (BMS, US) nivolumab and

    Merck & Cos MK-3475.

  • 8/10/2019 Ihs Global Pharma

    12/14

    1. The foundations for economicrecovery continue to be in place

    IHS Healthcare and Pharma Key Industry Drivers for 2014 I Copyright 2014 IHS

    Recent Multi-Client Studies

    Flexible Pricing Strategies: Maximizing Value across the Pharmaceutical Product Lifecycle

    Tiered Pricing Strategies in the Global Pharmaceutical Industry: Matching Prices with Local MarketConditions

    Pharmaco-economic Evaluation and ITR Reforms in France: Optimising Market Access Strategies

    Drug Price Erosion:Safeguarding Pharmaceutical Assets Against Value Attrition

    International Reference Pricing:A Strategic Guidebook to the New Global Pharmaceutical Pricing Paradigm

    Biosimilars and Non-Innovator Biologics in Emerging Markets:Payer, Regulator, and Pharma Strategies

    European Pharmacovigilance Reform:Implications for Market Access Strategies

    Payer-Industry Partnerships in the Emerging Markets:Best Practices for Successful Market Access of New

    Pharmaceuticals

    The New REAlity of Relative Effectiveness:An International Comparison of Evolving Requirements

    Optimising Medical Device & Diagnostic Launches:A Country-Specific Analysis

    Payer-Industry Partnerships:Best Practices for Successful Market Access of New Pharmaceuticals

  • 8/10/2019 Ihs Global Pharma

    13/14

    1. The foundatio

Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.